glycine and Venous Thrombosis studies

glycine and Venous Thrombosis

glycine has been researched along with Venous Thrombosis in 30 studies

Venous Thrombosis: The formation or presence of a blood clot (THROMBUS) within a vein.

Research Excerpts

Excerpt	Relevance	Reference
"The aims of this proof-of-concept study in patients undergoing total knee replacement (TKR) or total hip replacement (THR) were to determine whether LY517717 can safely reduce the risk of venous thromboembolism (VTE) and to identify at least one dose of LY517717 that is non-inferior to enoxaparin."	9.12	A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. ( Agnelli, G; Brandt, JT; Dmitrienko, A; Ginsberg, JS; Haas, S; Krueger, KA, 2007)
"Treatment with a fixed dose of oral ximelagatran, used without routine coagulation monitoring, showed reproducible pharmacokinetics and pharmacodynamics with a rapid onset of action and promising clinical results in patients with pulmonary embolism."	9.10	Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. ( Eriksson, H; Eriksson, UG; Lapidus, L; Larson, G; Olsson, CG; Thuresson, A; Wåhlander, K, 2002)
"The first clinical studies evaluating the safety and efficacy of melagatran, a novel, direct thrombin inhibitor, given subcutaneously as prophylaxis for venous thromboembolism (VTE) following total hip (THR) or total knee replacement (TKR) are reported."	9.10	Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. ( Ahnfelt, L; Arfwidsson, AC; Björkström, S; Elvander, CS; Eriksson, BI; Eriksson, UG; Folestad, A; Frison, L; Kälebo, P; Ogren, M; Sjöstedt, A, 2002)
"Ximelagatran (Exanta), the first available oral direct thrombin inhibitor, and its active form, melagatran, have been evaluated in the prevention of venous thromboembolism (VTE) in patients undergoing hip or knee replacement."	8.82	Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. ( Evans, HC; Faulds, D; Perry, CM, 2004)
"The antithrombotic and bleeding properties of the oral direct thrombin inhibitor ximelagatran and of warfarin were investigated in an experimental venous thrombosis and bleeding model in anaesthetized rats."	7.73	The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat. ( Carlsson, S; Elg, M, 2005)
"Melagatran 2 mg was started immediately before surgery; 3 mg was then administered postoperatively, followed by 24 mg of oral ximelagatran b."	6.71	The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. ( Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N, 2003)
"At bilateral venography, deep vein thrombosis was found in 20."	6.70	A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in ( Arfwidsson, AC; Bylock, A; Eriksson, BI; Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Kälebo, P, 2002)
"The aims of this proof-of-concept study in patients undergoing total knee replacement (TKR) or total hip replacement (THR) were to determine whether LY517717 can safely reduce the risk of venous thromboembolism (VTE) and to identify at least one dose of LY517717 that is non-inferior to enoxaparin."	5.12	A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. ( Agnelli, G; Brandt, JT; Dmitrienko, A; Ginsberg, JS; Haas, S; Krueger, KA, 2007)
"Treatment with a fixed dose of oral ximelagatran, used without routine coagulation monitoring, showed reproducible pharmacokinetics and pharmacodynamics with a rapid onset of action and promising clinical results in patients with pulmonary embolism."	5.10	Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. ( Eriksson, H; Eriksson, UG; Lapidus, L; Larson, G; Olsson, CG; Thuresson, A; Wåhlander, K, 2002)
"The first clinical studies evaluating the safety and efficacy of melagatran, a novel, direct thrombin inhibitor, given subcutaneously as prophylaxis for venous thromboembolism (VTE) following total hip (THR) or total knee replacement (TKR) are reported."	5.10	Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. ( Ahnfelt, L; Arfwidsson, AC; Björkström, S; Elvander, CS; Eriksson, BI; Eriksson, UG; Folestad, A; Frison, L; Kälebo, P; Ogren, M; Sjöstedt, A, 2002)
"Ximelagatran (Exanta), the first available oral direct thrombin inhibitor, and its active form, melagatran, have been evaluated in the prevention of venous thromboembolism (VTE) in patients undergoing hip or knee replacement."	4.82	Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. ( Evans, HC; Faulds, D; Perry, CM, 2004)
"The antithrombotic and bleeding properties of the oral direct thrombin inhibitor ximelagatran and of warfarin were investigated in an experimental venous thrombosis and bleeding model in anaesthetized rats."	3.73	The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat. ( Carlsson, S; Elg, M, 2005)
"Ximelagatran was to be initiated within the first two postoperative days."	2.71	Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. ( Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N, 2003)
"Melagatran clearance was correlated with renal function, assessed as calculated creatinine clearance."	2.71	Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. ( Eriksson, BI; Eriksson, UG; Frison, L; Gisleskog, PO; Gustafsson, D; Hamrén, B; Karlsson, MO; Mandema, JW; Wählby, U, 2003)
"Melagatran 2 mg was started immediately before surgery; 3 mg was then administered postoperatively, followed by 24 mg of oral ximelagatran b."	2.71	The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. ( Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N, 2003)
"At bilateral venography, deep vein thrombosis was found in 20."	2.70	A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in ( Arfwidsson, AC; Bylock, A; Eriksson, BI; Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Kälebo, P, 2002)
"The composite endpoint of screened deep vein thrombosis (DVT) and symptomatic pulmonary embolism (PE) during prophylaxis did not differ significantly between patients with or without these mutations."	2.70	Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. ( Andersson, C; Bylock, A; Eriksson, BI; Frison, L; Gustafsson, D; Larson, G; Lindahl, TL; Wåhlander, K, 2002)
" Oral ximelagatran dosing not only inhibits thrombin activity rapidly, competitively, and potently, but also delays and suppresses thrombin generation."	2.43	Ximelagatran--a promising new drug in thromboembolic disorders. ( Petersen, P, 2005)
" Furthermore, with no need for dosage adjustment or therapeutic drug monitoring there is emerging evidence that ximelagatran may replace warfarin as the anticoagulant of choice."	2.42	The METHRO trials. ( Hamaad, A; Lip, GY; Tayebjee, MH, 2003)
" In experimental models of thrombosis, melagatran has been shown to have a shallower dose-response curve than warfarin and, therefore, a better separation between efficacy and bleeding."	2.42	Oral direct thrombin inhibitors in clinical development. ( Gustafsson, D, 2003)
"Fondaparinux is a synthetic form of the natural pentasaccharide, its pharmacokinetics allows one s."	2.42	[Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents]. ( Drouet, L, 2003)
" Furthermore, vitamin K antagonists have a narrow therapeutic window that necessitates careful anticoagulation monitoring, and dosing is problematic because of multiple food and drug interactions."	2.42	Orally active direct thrombin inhibitors. ( Weitz, J, 2003)
"Melagatran has rapid onset of action, fixed twice-daily dosing, stable absorption, apparent low potential for medication interactions, and no requirement for monitoring drug levels or dose adjustment."	2.42	The direct thrombin inhibitor melagatran/ximelagatran. ( Brighton, TA, 2004)
" The elimination half-life of pentasaccharide is about 17 h, which allows a convenient once-daily dosing regime."	2.42	[New anticoagulants in clinical practice]. ( Boda, Z, 2004)
"Treatment of deep vein thrombosis is founded on the association of low molecular weight heparin and oral anticoagulant for three or six months."	2.41	[Treatment of deep vein thrombosis. Current and future questions]. ( Fiessinger, JN, 2001)
"Ximelagatran was well tolerated, with no clinically relevant changes in laboratory variables or vital signs."	1.33	The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation. ( Eriksson, UG; Hellgren, M; Johansson, S; Wåhlander, K, 2005)
"In a rat venous thrombosis model, animals were openly randomized to receive subcutaneously (s."	1.32	Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat. ( Börjesson, I; Carlsson, S; Elg, M, 2003)

Research

Studies (30)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	30 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

30 (100.00)

29.6817

2010's

0 (0.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Wåhlander, K	3
Lapidus, L	1
Olsson, CG	1
Thuresson, A	1
Eriksson, UG	5
Larson, G	2
Eriksson, H	1
Eriksson, BI	6
Agnelli, G	3
Cohen, AT	2
Dahl, OE	2
Mouret, P	2
Rosencher, N	2
Eskilson, C	2
Nylander, I	1
Frison, L	5
Ogren, M	2
Hamaad, A	1
Tayebjee, MH	1
Lip, GY	1
Mandema, JW	1
Karlsson, MO	1
Gisleskog, PO	1
Wählby, U	1
Hamrén, B	1
Gustafsson, D	4
Elg, M	2
Börjesson, I	1
Carlsson, S	2
Drouet, L	1
Weltermann, A	1
Kyrle, PA	1
Eichinger, S	1
Lassen, MR	1
Kälebo, P	3
Panfilov, S	1
Andersson, M	1
Freij, A	1
Evans, HC	1
Perry, CM	1
Faulds, D	1
Salam, AM	1
Al-Mousa, EN	1
Weitz, J	1
Caspary, L	1
Bauersachs, R	1
Brehme, S	1
Creutzig, A	1
Harenberg, J	1
Hoffmann, U	1
Landgraf, H	1
Schellong, S	1
Brighton, TA	1
Cimminiello, C	1
Planès, A	1
Samama, MM	1
Boda, Z	1
Petersen, P	1
Hellgren, M	1
Johansson, S	1
Nielsen, JD	1
Meyer Samama, M	1
Folsom, AR	1
Haas, S	1
Ginsberg, JS	1
Krueger, KA	1
Dmitrienko, A	1
Brandt, JT	1
Triques, K	1
Piednoir, E	1
Dalmais, M	1
Schmidt, J	1
Le Signor, C	1
Sharkey, M	1
Caboche, M	1
Sturbois, B	1
Bendahmane, A	1
Heinzl, S	1
Arfwidsson, AC	2
Bylock, A	2
Fager, G	1
Fiessinger, JN	1
Lindahl, TL	1
Andersson, C	1
Ahnfelt, L	1
Björkström, S	1
Sjöstedt, A	1
Folestad, A	1
Elvander, CS	1

Studies

Wåhlander, K

Lapidus, L

Olsson, CG

Thuresson, A

Eriksson, UG

Larson, G

Eriksson, H

Eriksson, BI

Agnelli, G

Cohen, AT

Dahl, OE

Mouret, P

Rosencher, N

Eskilson, C

Nylander, I

Frison, L

Ogren, M

Hamaad, A

Tayebjee, MH

Lip, GY

Mandema, JW

Karlsson, MO

Gisleskog, PO

Wählby, U

Hamrén, B

Gustafsson, D

Elg, M

Börjesson, I

Carlsson, S

Drouet, L

Weltermann, A

Kyrle, PA

Eichinger, S

Lassen, MR

Kälebo, P

Panfilov, S

Andersson, M

Freij, A

Evans, HC

Perry, CM

Faulds, D

Salam, AM

Al-Mousa, EN

Weitz, J

Caspary, L

Bauersachs, R

Brehme, S

Creutzig, A

Harenberg, J

Hoffmann, U

Landgraf, H

Schellong, S

Brighton, TA

Cimminiello, C

Planès, A

Samama, MM

Boda, Z

Petersen, P

Hellgren, M

Johansson, S

Nielsen, JD

Meyer Samama, M

Folsom, AR

Haas, S

Ginsberg, JS

Krueger, KA

Dmitrienko, A

Brandt, JT

Triques, K

Piednoir, E

Dalmais, M

Schmidt, J

Le Signor, C

Sharkey, M

Caboche, M

Sturbois, B

Bendahmane, A

Heinzl, S

Arfwidsson, AC

Bylock, A

Fager, G

Fiessinger, JN

Lindahl, TL

Andersson, C

Ahnfelt, L

Björkström, S

Sjöstedt, A

Folestad, A

Elvander, CS

Reviews

14 reviews available for glycine and Venous Thrombosis

Article	Year
The METHRO trials. Expert opinion on investigational drugs, 2003, Volume: 12, Issue:5 Topics: Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Humans; Orthopedic Procedures; Prodrugs	2003
Oral direct thrombin inhibitors in clinical development. Journal of internal medicine, 2003, Volume: 254, Issue:4 Topics: Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Glycine; Hemostasis; Humans; P	2003
[Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents]. Bulletin de l'Academie nationale de medecine, 2003, Volume: 187, Issue:1 Topics: Administration, Oral; Azetidines; Benzylamines; Clinical Trials as Topic; Coronary Thrombosis; Facto	2003
Novel anticoagulants for the prevention and treatment of venous thromboembolism. Wiener medizinische Wochenschrift (1946), 2003, Volume: 153, Issue:19-20 Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation Factors; Drugs, Investigational; Fondapa	2003
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Drugs, 2004, Volume: 64, Issue:6 Topics: Anticoagulants; Azetidines; Benzylamines; Drug Interactions; Drug Therapy, Combination; Enoxaparin;	2004
The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trials. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:6 Topics: Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Clinical Trials as Topic; Coronary Ar	2004
Orally active direct thrombin inhibitors. Seminars in vascular medicine, 2003, Volume: 3, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Blood Coagulati	2003
[Prevention and treatment of deep vein thrombosis with ximelagatran]. Deutsche medizinische Wochenschrift (1946), 2004, Jul-23, Volume: 129, Issue:30 Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Fondaparinux; Glycine; Heparin; Hirudin Therapy;	2004
The direct thrombin inhibitor melagatran/ximelagatran. The Medical journal of Australia, 2004, Oct-18, Volume: 181, Issue:8 Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Glycine; Humans; Myocardial Infarction;	2004
[New anticoagulants in clinical practice]. Orvosi hetilap, 2004, Dec-05, Volume: 145, Issue:49 Topics: Anticoagulants; Azetidines; Benzylamines; Fondaparinux; Glycine; Humans; Polysaccharides; Protein C;	2004
Ximelagatran--a promising new drug in thromboembolic disorders. Current pharmaceutical design, 2005, Volume: 11, Issue:4 Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Glycine; Humans; Prodrugs; Randomize	2005
[Thromboprophylaxis in hip and knee arthroplasty. Are the new anticoagulants better than those previously used?]. Ugeskrift for laeger, 2005, May-23, Volume: 167, Issue:21 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzyla	2005
[The new antithrombotic agents]. Presse medicale (Paris, France : 1983), 2005, Oct-22, Volume: 34, Issue:18 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylami	2005
[Treatment of deep vein thrombosis. Current and future questions]. Bulletin de l'Academie nationale de medecine, 2001, Volume: 185, Issue:8 Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Glycine; Hemorrhage; Heparin, Low-Mo	2001

Article

Year

The METHRO trials.

Expert opinion on investigational drugs, 2003, Volume: 12, Issue:5

Topics: Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Humans; Orthopedic Procedures; Prodrugs

2003

Oral direct thrombin inhibitors in clinical development.

Journal of internal medicine, 2003, Volume: 254, Issue:4

Topics: Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Glycine; Hemostasis; Humans; P

2003

[Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents].

Bulletin de l'Academie nationale de medecine, 2003, Volume: 187, Issue:1

Topics: Administration, Oral; Azetidines; Benzylamines; Clinical Trials as Topic; Coronary Thrombosis; Facto

2003

Novel anticoagulants for the prevention and treatment of venous thromboembolism.

Wiener medizinische Wochenschrift (1946), 2003, Volume: 153, Issue:19-20

Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation Factors; Drugs, Investigational; Fondapa

2003

Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.

Drugs, 2004, Volume: 64, Issue:6

Topics: Anticoagulants; Azetidines; Benzylamines; Drug Interactions; Drug Therapy, Combination; Enoxaparin;

2004

The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trials.

Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:6

Topics: Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Clinical Trials as Topic; Coronary Ar

2004

Orally active direct thrombin inhibitors.

Seminars in vascular medicine, 2003, Volume: 3, Issue:2

Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Blood Coagulati

2003

[Prevention and treatment of deep vein thrombosis with ximelagatran].

Deutsche medizinische Wochenschrift (1946), 2004, Jul-23, Volume: 129, Issue:30

Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Fondaparinux; Glycine; Heparin; Hirudin Therapy;

2004

The direct thrombin inhibitor melagatran/ximelagatran.

The Medical journal of Australia, 2004, Oct-18, Volume: 181, Issue:8

Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Glycine; Humans; Myocardial Infarction;

2004

[New anticoagulants in clinical practice].

Orvosi hetilap, 2004, Dec-05, Volume: 145, Issue:49

Topics: Anticoagulants; Azetidines; Benzylamines; Fondaparinux; Glycine; Humans; Polysaccharides; Protein C;

2004

Ximelagatran--a promising new drug in thromboembolic disorders.

Current pharmaceutical design, 2005, Volume: 11, Issue:4

Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Glycine; Humans; Prodrugs; Randomize

2005

[Thromboprophylaxis in hip and knee arthroplasty. Are the new anticoagulants better than those previously used?].

Ugeskrift for laeger, 2005, May-23, Volume: 167, Issue:21

Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzyla

2005

[The new antithrombotic agents].

Presse medicale (Paris, France : 1983), 2005, Oct-22, Volume: 34, Issue:18

Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylami

2005

[Treatment of deep vein thrombosis. Current and future questions].

Bulletin de l'Academie nationale de medecine, 2001, Volume: 185, Issue:8

Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Glycine; Hemorrhage; Heparin, Low-Mo

2001

Trials

8 trials available for glycine and Venous Thrombosis

Article	Year
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thrombosis research, 2002, Aug-15, Volume: 107, Issue:3-4 Topics: Administration, Oral; Adult; Aged; Azetidines; Benzylamines; Female; Fibrinolytic Agents; Glycine; H	2002
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thrombosis and haemostasis, 2003, Volume: 89, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip	2003
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clinical pharmacokinetics, 2003, Volume: 42, Issue:7 Topics: Administration, Cutaneous; Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Repla	2003
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac	2003
A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:4 Topics: Adult; Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dose-Response Relation	2007
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Thrombosis and haemostasis, 2002, Volume: 87, Issue:2 Topics: Administration, Oral; Adolescent; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement	2002
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thrombosis and haemostasis, 2002, Volume: 87, Issue:4 Topics: Activated Protein C Resistance; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthropl	2002
Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. Thrombosis research, 2002, Mar-01, Volume: 105, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen	2002

Article

Year

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.

Thrombosis research, 2002, Aug-15, Volume: 107, Issue:3-4

Topics: Administration, Oral; Adult; Aged; Azetidines; Benzylamines; Female; Fibrinolytic Agents; Glycine; H

2002

Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.

Thrombosis and haemostasis, 2003, Volume: 89, Issue:2

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip

2003

Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.

Clinical pharmacokinetics, 2003, Volume: 42, Issue:7

Topics: Administration, Cutaneous; Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Repla

2003

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.

Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:12

Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac

2003

A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement.

Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:4

Topics: Adult; Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dose-Response Relation

2007

A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in

Thrombosis and haemostasis, 2002, Volume: 87, Issue:2

Topics: Administration, Oral; Adolescent; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement

2002

Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.

Thrombosis and haemostasis, 2002, Volume: 87, Issue:4

Topics: Activated Protein C Resistance; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthropl

2002

Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies.

Thrombosis research, 2002, Mar-01, Volume: 105, Issue:5

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen

2002

Other Studies

8 other studies available for glycine and Venous Thrombosis

Article	Year
Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat. Biopharmaceutics & drug disposition, 2003, Volume: 24, Issue:6 Topics: Animals; Antithrombins; Azetidines; Benzylamines; Chemistry, Pharmaceutical; Constriction, Pathologi	2003
Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study. Journal of thrombosis and haemostasis : JTH, 2004, Volume: 2, Issue:11 Topics: Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Dissent and Disputes; Enoxaparin	2004
The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation. BJOG : an international journal of obstetrics and gynaecology, 2005, Volume: 112, Issue:5 Topics: Administration, Oral; Adult; Anticoagulants; Azetidines; Benzylamines; Breast Feeding; Female; Glyci	2005
The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2005, Volume: 16, Issue:4 Topics: Animals; Azetidines; Benzylamines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Ev	2005
Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy. Prescrire international, 2005, Volume: 14, Issue:78 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Fibrino	2005
Addendum to "Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism". American journal of hematology, 2007, Volume: 82, Issue:7 Topics: Case-Control Studies; Genetic Predisposition to Disease; Glycine; Humans; Incidence; Polymorphism, G	2007
Mutation detection using ENDO1: application to disease diagnostics in humans and TILLING and Eco-TILLING in plants. BMC molecular biology, 2008, Apr-23, Volume: 9 Topics: Alanine; Amino Acid Substitution; Arabidopsis; Arabidopsis Proteins; Base Sequence; Deoxyribonucleas	2008
[New thrombolytic agents]. Medizinische Monatsschrift fur Pharmazeuten, 2001, Volume: 24, Issue:2 Topics: Anticoagulants; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Heparin; Humans; Thrombosis;	2001

Article

Year

Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.

Biopharmaceutics & drug disposition, 2003, Volume: 24, Issue:6

Topics: Animals; Antithrombins; Azetidines; Benzylamines; Chemistry, Pharmaceutical; Constriction, Pathologi

2003

Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study.

Journal of thrombosis and haemostasis : JTH, 2004, Volume: 2, Issue:11

Topics: Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Dissent and Disputes; Enoxaparin

2004

The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.

BJOG : an international journal of obstetrics and gynaecology, 2005, Volume: 112, Issue:5

Topics: Administration, Oral; Adult; Anticoagulants; Azetidines; Benzylamines; Breast Feeding; Female; Glyci

2005

The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2005, Volume: 16, Issue:4

Topics: Animals; Azetidines; Benzylamines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Ev

2005

Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.

Prescrire international, 2005, Volume: 14, Issue:78

Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Fibrino

2005

Addendum to "Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism".

American journal of hematology, 2007, Volume: 82, Issue:7

Topics: Case-Control Studies; Genetic Predisposition to Disease; Glycine; Humans; Incidence; Polymorphism, G

2007

Mutation detection using ENDO1: application to disease diagnostics in humans and TILLING and Eco-TILLING in plants.

BMC molecular biology, 2008, Apr-23, Volume: 9

Topics: Alanine; Amino Acid Substitution; Arabidopsis; Arabidopsis Proteins; Base Sequence; Deoxyribonucleas

2008

[New thrombolytic agents].

Medizinische Monatsschrift fur Pharmazeuten, 2001, Volume: 24, Issue:2

Topics: Anticoagulants; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Heparin; Humans; Thrombosis;

2001